Abiopharma

🔍 Kaseta Michael (Executive)

Company: Liquidia Corp (LQDA)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Acquired 2,344 shares of Common Stock (Direct)
  Date: 2025-08-29 | Code: M | equity_swap_involved: 0 | shares_owned_after: 359,596.00 | transaction_form_type: 4 | Footnotes: F2, F1, F3
• Sold 1,148 shares of Common Stock at $29.05 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 358,448.00 | transaction_form_type: 4 | Footnotes: F4, F5, F2, F3
• Sold 2,344 shares of Restricted Stock Unit (Derivative)
  Date: 2025-08-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,687.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis
• F2: On January 16, 2022, the Reporting Person was granted 37,500 RSUs with 25% vesting on February 28, 2023 and the remaining RSUs vesting ratably on a quarterly basis over three years thereafter. Of those RSUs, a total of 32,813 have vested as of the date of this Form 4.
• F3: Includes (i) 46,750 unvested RSUs of the 124,667 RSUs granted to the Reporting Person on January 11, 2023, (ii) 58,281 unvested RSUs and 31,250 unvested RSUs of the 93,250 RSUs and 50,000 RSUs granted to the Reporting Person on January 11, 2024 and January 15, 2024, respectively, (iii) 112,797 RSUs granted to the Reporting Person on January 11, 2025, none of which have vested as of the date of this Form 4 and (iv) 11,257 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
• F4: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• F5: These shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 16, 2022.